Author: Michael

A virtual mesothelioma cancer trial recently got underway via Zoom in a Washington state court with each side presenting their opening arguments to the 16 person jury in Seattle. King County, Wash., is one of the most active jurisdictions in the country when it comes to virtual hearings during coronavirus pandemic. The judge presiding over the case did so from her courtroom, while all the other parties logged into Zoom from their remote locations.

Asbestos is a naturally occurring mineral once commonly used in many industrial, commercial, and military applications for its heat-resistant properties. Sadly, the substance is also causally related to developing mesothelioma, a rare and deadly form of cancer that typically affects the thin lining of tissue surrounding the lungs and abdomen. Despite what many asbestos-industry advocates purported throughout the years, there is no safe or acceptable level of asbestos exposure, nor is there any type of asbestos less prone to causing mesothelioma.

A recently published study from the Netherlands appears to indicate that a combination of a pair of immunotherapy drugs can help improve the prognosis of mesothelioma patients with tumors that are not able to be removed through surgery. The experiment, named checkmate 743, compared the use of first-line nivolumab and ipilimumab versus platinum-based chemotherapy in a group of over 600 mesothelioma cancer patients, and showed significant tumor shrinkage for a large portion of the participants who were given the two-drug combination.

10 U.S. states and the District of Columbia recently filed a lawsuit against the Environmental Protection Agency (EPA) to force the agency to tighten rules regarding the oversight of asbestos and reduce the possible harm to the public posed by the mineral’s use. The suit is being led by the states attorneys general of California and Massachusetts, Xavier Becerra and Maura Healey, with Connecticut, Hawaii, Maine, Maryland, Minnesota, New Jersey, Oregon, Washington, and the District of Columbia joining.

Recently, the Department of Justice (DOJ) took a firm stand against giant pharmaceutical company Johnson & Johnson (J&J) after the company tried to file for bankruptcy again. Johnson & Johnson is facing mesothelioma and ovarian cancer lawsuits from tens of thousands of victims who blame the asbestos-contaminated talc in the company’s famous baby powder for their illness. To address these claims, J&J has repeatedly attempted a controversial strategy of filing for bankruptcy. Many people thought that J&J’s latest bankruptcy filing attempt would succeed.

Scientists from the United Kingdom recently published a study outlining a potentially significant breakthrough in the fight against aggressive colon, lung, and breast cancers by identifying the genetic markers regulating cancer growth. In their report, the researchers demonstrated tumor growth may be decreased as much as 75% when scientists targeting one-specific gene and noted that 18 others either aid in tumor growth or can slow down the metastasization.